Gilead Raises Number of Participants in Coronavirus Drug Test - (TheStreet via NewsPoints Desk)

  • According to the site ClinicalTrials.gov, Gilead Sciences has more than doubled the number of participants in its studies for potential COVID-19 treatment remdesivir, reported TheStreet.

  • Gilead has increased the number of participants in its global, randomized, open-label Phase III test for those afflicted with moderate coronavirus symptoms to 1600 from 600.

  • The company boosted the number of patients with severe symptoms being tested with the drug to 2400 from 400.

  • Meanwhile, Gilead expects initial results from the tests in May. Previously, the company said it plans to make 500,000 treatment courses of remdesivir by October and 1 million by year-end.

To read more NewsPoints articles, click here.